Skip to main content

Table 2 Drug-related grade 3/4 skin, gastrointestinal, and hepatobiliary AEs during VEM1-IPI by investigator-reported preferred term

From: Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

AE Organ Category, n (%)a VEM1-IPI (n = 46)
Skin 15 (32.6)
 Rash 9 (19.6)
 Erythema 2 (4.3)
 Exfoliative rash 2 (4.3)
 Pruritus 2 (4.3)
 Rash generalized 2 (4.3)
 Rash maculo-papular 1 (2.2)
Gastrointestinal disorders 10 (21.7)
 Diarrhea 5 (10.9)
 Colitis 2 (4.3)
 Nausea 2 (4.3)
 Abdominal pain 1 (2.2)
 Autoimmune colitis 1 (2.2)
 Vomiting 1 (2.2)
Hepatobiliary disorders 2 (4.3)
 Hepatitis 1 (2.2)
 Hyperbilirubinemia 1 (2.2)
  1. AE adverse event, IPI ipilimumab, VEM vemurafenib
  2. aPatients may have experienced more than 1 event